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Psychiatric disorders are not diff erent from other 
disorders in that there etiology is complex. Envi-
ronmental and genetic factors contribute to their 
pathogenesis. Th eir relative contribution though dif-
fers between disorders and between individual cases. 
With regard to genetic factors one has to diff erentiate 
between rare familial cases with Mendelian inherit-
ance and causative genes and the majority of sporadic 
cases in which the contribution of individual suscep-
tibility genes is small. One example is dementia of 
Alzheimer type. While in a small group of families 
mutations in genes such as Presenilin 1, Presenilin 2 
and Amyloid Precursor Protein are causing a domi-
nantly inherited form of Alzheimer’s disease, in the 
overwhelming majority of sporadic cases the major 
susceptility gene ApoE is associated with a 3-4 fold 
increased risk for the disorder, but by itself is not able 
to cause it. As a consequence numerous individuals 
with the ApoE risk variant never will succumb to 
Alzheimer’s disease. Also in other mental disorders 
such as schizophrenia, bipolar aff ective disorder, uni-
polar depression and anxiety disorders the situation is 
similar. Disease loci have been identifi ed in linkage 
studies in schizophrenic and bipolar aff ective fami-
lies some of which including the putative causative 
genes have been replicated in metaanalyses. Numer-
ous candidate gene association studies to identify 
susceptibility genes have been performed in patient 
versus control cohorts mostly with ambiguous results. 
Recently, genome wide association studies have be-
come possible allowing with their hypothesis free ap-
proach the identifi cation of novel genes and pathways. 
While these genes like ApoE will not be of diagnostic 
or predictive value, they may well help to contribute to 
the development of novel therapeutic approaches. In 
fact, the fi rst practical application of genetic fi ndings 
may come  in the fi eld of pharmacogenetics. Simliar 
to already established procedures in oncology, iden-
tifi cation of genetic variants prior to the initiation of 
pharmacotherapy may contribute to a more individu-
alized therapy in the future.
